TN2009000137A1 - Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis - Google Patents

Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Info

Publication number: TN2009000137A1
Authority: TN; Tunisia
Prior art keywords: dihydroimidazo; diseases associated; angiogenesis; substituted; proliferative disorders
Prior art date: 2006-12-05

Application number

TNP2009000137A

Other languages

English (en)

Inventor

Martin Hentemann

Jill Wood

William Scott

Martin Michels

Ann-Marie Campbell

Ann-Marie Bullion

R Bruce Rowley

Aniko Redman

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-05

Filing date

2009-04-13

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000137(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-13 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2010-10-18 Publication of TN2009000137A1 publication Critical patent/TN2009000137A1/fr

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical class C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 title abstract 2
230000033115 angiogenesis Effects 0.000 title abstract 2
201000010099 disease Diseases 0.000 title abstract 2
230000003463 hyperproliferative effect Effects 0.000 title abstract 2
208000035475 disorder Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Plant Pathology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)

TNP2009000137A 2006-12-05 2009-04-13 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis TN2009000137A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87309006P	2006-12-05	2006-12-05
PCT/US2007/024985 WO2008070150A1 (fr)	2006-12-05	2007-12-05	Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse

Publications (1)

Publication Number	Publication Date
TN2009000137A1 true TN2009000137A1 (en)	2010-10-18

Family

ID=39492563

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000137A TN2009000137A1 (en)	2006-12-05	2009-04-13	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Country Status (41)

Country	Link
US (3)	US8466283B2 (fr)
EP (1)	EP2096919B1 (fr)
JP (1)	JP5326092B2 (fr)
KR (1)	KR101501785B1 (fr)
CN (4)	CN108774232B (fr)
AR (1)	AR064106A1 (fr)
AU (1)	AU2007328008B2 (fr)
BR (1)	BRPI0720178B8 (fr)
CA (1)	CA2671614C (fr)
CL (1)	CL2007003508A1 (fr)
CO (1)	CO6220908A2 (fr)
CR (1)	CR10838A (fr)
CU (1)	CU23796B7 (fr)
DK (1)	DK2096919T3 (fr)
DO (1)	DOP2009000135A (fr)
EA (1)	EA018839B1 (fr)
EC (1)	ECSP099387A (fr)
ES (1)	ES2572189T3 (fr)
GT (1)	GT200900154A (fr)
HN (1)	HN2009001131A (fr)
HU (1)	HUE028773T2 (fr)
IL (1)	IL198273A (fr)
JO (1)	JO3147B1 (fr)
MA (1)	MA31283B1 (fr)
MX (1)	MX2009006001A (fr)
MY (1)	MY157944A (fr)
NO (1)	NO342348B1 (fr)
NZ (1)	NZ577342A (fr)
PA (1)	PA8759601A1 (fr)
PE (1)	PE20081444A1 (fr)
PL (1)	PL2096919T3 (fr)
RS (1)	RS56045B1 (fr)
SG (1)	SG177170A1 (fr)
SI (1)	SI2096919T1 (fr)
SV (1)	SV2009003288A (fr)
TN (1)	TN2009000137A1 (fr)
TW (1)	TWI406662B (fr)
UA (1)	UA96965C2 (fr)
UY (1)	UY30761A1 (fr)
WO (1)	WO2008070150A1 (fr)
ZA (1)	ZA200904691B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2713388C (fr) *	2008-01-14	2016-03-29	William Scott	Derives de 2,3-dihydroimidazo [1,2-c] quinazoline a substitution sulfone utilises pour traiter des troubles hyperproliferants et des maladies associees a l'angiogenese
EP2168583A1 (fr) *	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
EP2168582A1 (fr)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Combinaisons de 2,3-dihydroimidazo[1,2-c]quinazolines substituées
US8791131B2 (en) *	2008-09-30	2014-07-29	Pfizer Inc.	Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
EP2184276A1 (fr)	2008-11-07	2010-05-12	Universite Paul Cezanne Aix-Marseille Iii	Procédé de préparation de nouvelles 1H-benzo(d) imidazol-2(3h)-ones substituées, de nouveaux intermédiaires et leur utilisation en tant qu'inhibiteurs de bace 1
US8648190B2 (en)	2009-01-16	2014-02-11	Daiso Co., Ltd.	Process for producing 2-hydroxymethylmorpholine salt
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EA201201414A8 (ru) *	2010-04-16	2013-12-30	Байер Интеллектчуал Проперти Гмбх	КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
EP2582709B1 (fr)	2010-06-18	2018-01-24	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103298469A (zh)	2010-08-31	2013-09-11	首尔大学校产学协力财团	PPARδ激动剂的胎儿重编程的用途
US9675616B2 (en)	2010-11-11	2017-06-13	Bayer Intellectual Property Gmbh	Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines
CN103339133B (zh) *	2010-11-11	2016-06-15	拜耳知识产权有限责任公司	烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
UA113280C2 (xx) *	2010-11-11	2017-01-10		АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (fr) *	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
JO3733B1 (ar)	2011-04-05	2021-01-31	Bayer Ip Gmbh	استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr)	2011-09-27	2015-10-21	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
JP6427097B2 (ja)	2012-06-15	2018-11-21	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	癌を処置するための組成物および該組成物を製造するための方法
WO2014068070A1 (fr)	2012-10-31	2014-05-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés pour prévenir le syndrome des antiphospholipides (sapl)
KR102185175B1 (ko) *	2012-11-02	2020-12-02	티지 쎄라퓨틱스, 인코포레이티드	항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물
CN103214489B (zh) *	2013-02-25	2016-10-26	中国人民解放军第二军医大学	一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
AP2015008750A0 (en)	2013-04-08	2015-09-30	Bayer Pharma AG	Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
CN104557955B (zh) *	2013-10-23	2017-05-03	上海汇伦生命科技有限公司	作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
WO2015081127A2 (fr) *	2013-11-26	2015-06-04	Gilead Sciences, Inc.	Therapies pour le traitement de troubles myeloproliferatifs
WO2015082378A1 (fr)	2013-12-03	2015-06-11	Bayer Pharma Aktiengesellschaft	Combinaison d'inhibiteurs de la pi3k
CN105934256B (zh) *	2013-12-03	2019-12-27	拜耳制药股份公司	Pi3k-抑制剂的组合产品
TWI533869B (zh)	2014-03-11	2016-05-21	國立中央大學	蒽醌［２，１－ｃ］［１，２，５］噻二唑－６，１１－二酮化合物緩解疼痛的應用
TWI533871B (zh)	2014-03-11	2016-05-21	國立中央大學	萘并［２，３－ｆ］喹喔啉－７，１２－二酮化合物緩解疼痛的應用
FR3018813B1 (fr) *	2014-03-18	2016-04-15	Maco Pharma Sa	Procede de synthese d'un derive de psoralene
WO2016059220A1 (fr)	2014-10-16	2016-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Agents d'activation du tcr à utiliser dans le traitement de la lla-t
EP3018131A1 (fr) *	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthèse de copanlisib et son sel de dichlorhydrate
EP3018127A1 (fr) *	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthèse de copanlisib et son sel de dichlorhydrate
EA201791974A1 (ru) *	2015-03-09	2018-05-31	Байер Фарма Акциенгезельшафт	Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2016142313A1 (fr) *	2015-03-09	2016-09-15	Bayer Pharma Aktiengesellschaft	Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées
FR3033499A1 (fr) *	2015-03-11	2016-09-16	Centre Leon-Berard	Composition pour le traitement des tumeurs neuroendocrines pancreatiques
CN111909173B (zh) *	2015-07-02	2025-03-04	豪夫迈·罗氏有限公司	苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
CN105130998B (zh) *	2015-09-25	2017-07-28	苏州立新制药有限公司	库潘尼西的制备方法
CN105130997B (zh) *	2015-09-25	2017-12-05	苏州明锐医药科技有限公司	一种库潘尼西的制备方法
WO2017153220A1 (fr)	2016-03-08	2017-09-14	Bayer Pharma Aktiengesellschaft	2-amino-n-[7-méthoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (fr)	2016-03-17	2017-09-20	Bayer Pharma Aktiengesellschaft	Combinaisons de copanlisib
US10925869B2 (en) *	2016-05-26	2021-02-23	University of Pittsburgh—of the Commonwealth System of Higher Education	Compositions and methods for treating pulmonary vascular disease
CN108368117B (zh) *	2016-06-08	2021-03-02	深圳市塔吉瑞生物医药有限公司	一种取代的咪唑并喹唑啉化合物及其药物组合物
WO2018054782A1 (fr)	2016-09-23	2018-03-29	Bayer Pharma Aktiengesellschaft	Combinaison d'inhibiteurs de la pi3k
CN106177918A (zh) *	2016-09-30	2016-12-07	广州赛莱拉干细胞科技股份有限公司	一种间充质干细胞注射液及其制备方法和应用
AU2017376766A1 (en)	2016-12-14	2019-06-06	Tva (Abc), Llc	HSP90-targeting conjugates and formulations thereof
CA3054249A1 (fr)	2017-02-24	2018-08-30	Bayer Pharma Aktiengesellschaft	Combinaisons de copanlisib avec un anticorps anti-pd-1
WO2018215282A1 (fr)	2017-05-26	2018-11-29	Bayer Pharma Aktiengesellschaft	Combinaison d'inhibiteurs de bub1 et de pi3k
CA3068324A1 (fr)	2017-06-28	2019-01-03	Bayer Consumer Care Ag	Combinaison d'un inhibiteur de pi3k et d'un antagoniste du recepteur des androgenes
WO2019010491A1 (fr) *	2017-07-07	2019-01-10	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Combinaisons de médicaments pour la protection contre la mort des cellules neuronales
JP6916562B2 (ja) *	2017-08-11	2021-08-11	テリジーンリミテッドＴｅｌｉｇｅｎｅＬｔｄ．	化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤
WO2019048527A1 (fr)	2017-09-08	2019-03-14	Bayer Pharma Aktiengesellschaft	Formulations de copanlisib
EP3498266A1 (fr)	2017-12-15	2019-06-19	Bayer Consumer Care AG	Formulations de copanlisib
WO2019105734A1 (fr)	2017-11-28	2019-06-06	Bayer Consumer Care Ag	Combinaisons de copanlisib
WO2019105835A1 (fr)	2017-11-29	2019-06-06	Bayer Consumer Care Ag	Combinaisons de copanlisib et d'anetumab ravtansine
WO2019197269A1 (fr)	2018-04-11	2019-10-17	Bayer Aktiengesellschaft	Combinaisons de copanlisib et de dérivés de triazolone ainsi que leur utilisation dans le traitement du cancer
CN108383849B (zh) *	2018-04-26	2020-11-06	浙江大学	咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用
CN108841318A (zh) *	2018-07-12	2018-11-20	中国科学院海洋研究所	一种自修复壳聚糖水凝胶防腐涂料及其合成方法
US20210187134A1 (en)	2018-08-28	2021-06-24	Bayer As	Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (fr)	2018-10-16	2021-08-25	Bayer Aktiengesellschaft	Combinaison d'inhibiteurs de kinase atr avec des composés de 2,3-dihydro-imidazo[1,2-c]quinazoline
CN109516961B (zh)	2018-12-25	2021-01-01	浙江大学	氨基喹唑啉酮和氨基异喹啉酮衍生物及其应用
WO2020164997A1 (fr)	2019-02-12	2020-08-20	Bayer Aktiengesellschaft	Combinaison d'inhibiteurs de la pi3k
US12653785B2 (en)	2020-05-21	2026-06-16	University of Pittsburgh—of the Commonwealth System of Higher Education	Compositions and methods for administering a YAP1/WWRT1 inhibiting composition and a GLS1 inhibiting composition
WO2023101359A1 (fr) *	2021-11-30	2023-06-08	광주과학기술원	Composition comprenant un inhibiteur de pip4k2c comme principe actif pour le traitement du cancer
WO2023139125A1 (fr)	2022-01-18	2023-07-27	Synthon B.V.	Procédé amélioré de préparation de copanlisib
WO2023218032A1 (fr)	2022-05-13	2023-11-16	Synthon B.V.	Formes solides de sels de copanlisib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644354A (en)	1968-09-16	1972-02-22	Sandoz Ag	5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4146718A (en) *	1978-04-10	1979-03-27	Bristol-Myers Company	Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
EP1277754B8 (fr) *	2000-04-27	2005-09-28	Astellas Pharma Inc.	Derives d'imidazopyridine
US6608053B2 (en) *	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
PA8578001A1 (es) *	2002-08-07	2004-05-07	Warner Lambert Co	Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004029055A1 (fr) *	2002-09-30	2004-04-08	Bayer Pharmaceuticals Corporation	Derives d'azole-pyrimidines fondues
JP2007501863A (ja) *	2003-06-12	2007-02-01	メルク　エンド　カムパニー　インコーポレーテッド	有糸分裂キネシン阻害剤
AT412873B (de)	2004-02-20	2005-08-25	Aop Orphan Pharmaceuticals Ag	Verfahren zur herstellung von anagrelid hydrochlorid
WO2007143483A2 (fr)	2006-06-01	2007-12-13	Smithkline Beecham Corporation	Procédé de traitement du cancer
WO2008002039A1 (fr)	2006-06-28	2008-01-03	Hanmi Pharm. Co., Ltd.	Dérivés de quinazoline destinés à inhiber le développement de cellules cancéreuses
EP2508525A1 (fr)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés

2007
- 2007-12-03 AR ARP070105390A patent/AR064106A1/es active IP Right Grant
- 2007-12-04 PA PA20078759601A patent/PA8759601A1/es unknown
- 2007-12-04 PE PE2007001709A patent/PE20081444A1/es active IP Right Grant
- 2007-12-04 UY UY30761A patent/UY30761A1/es not_active Application Discontinuation
- 2007-12-04 TW TW096145999A patent/TWI406662B/zh not_active IP Right Cessation
- 2007-12-04 JO JOP/2007/0517A patent/JO3147B1/ar active
- 2007-12-05 RS RS20170561A patent/RS56045B1/sr unknown
- 2007-12-05 EP EP07862580.3A patent/EP2096919B1/fr active Active
- 2007-12-05 JP JP2009540293A patent/JP5326092B2/ja not_active Expired - Fee Related
- 2007-12-05 CA CA2671614A patent/CA2671614C/fr active Active
- 2007-12-05 CN CN201810535933.9A patent/CN108774232B/zh active Active
- 2007-12-05 CN CN201510632842.3A patent/CN105254634B/zh not_active Expired - Fee Related
- 2007-12-05 PL PL07862580T patent/PL2096919T3/pl unknown
- 2007-12-05 US US12/517,875 patent/US8466283B2/en not_active Ceased
- 2007-12-05 MX MX2009006001A patent/MX2009006001A/es active IP Right Grant
- 2007-12-05 US US15/398,916 patent/USRE46856E1/en not_active Expired - Fee Related
- 2007-12-05 AU AU2007328008A patent/AU2007328008B2/en not_active Ceased
- 2007-12-05 HU HUE07862580A patent/HUE028773T2/en unknown
- 2007-12-05 EA EA200900733A patent/EA018839B1/ru not_active IP Right Cessation
- 2007-12-05 CL CL200703508A patent/CL2007003508A1/es unknown
- 2007-12-05 KR KR1020097011551A patent/KR101501785B1/ko not_active Expired - Fee Related
- 2007-12-05 CN CN200780044849.7A patent/CN101631464B/zh active Active
- 2007-12-05 SI SI200731771A patent/SI2096919T1/sl unknown
- 2007-12-05 CN CN202211453281.7A patent/CN115724847A/zh active Pending
- 2007-12-05 DK DK07862580.3T patent/DK2096919T3/en active
- 2007-12-05 NZ NZ577342A patent/NZ577342A/en not_active IP Right Cessation
- 2007-12-05 BR BRPI0720178A patent/BRPI0720178B8/pt not_active IP Right Cessation
- 2007-12-05 SG SG2011088887A patent/SG177170A1/en unknown
- 2007-12-05 WO PCT/US2007/024985 patent/WO2008070150A1/fr not_active Ceased
- 2007-12-05 UA UAA200906701A patent/UA96965C2/ru unknown
- 2007-12-05 ES ES07862580T patent/ES2572189T3/es active Active
- 2007-12-05 MY MYPI20092044A patent/MY157944A/en unknown
2009
- 2009-04-13 TN TNP2009000137A patent/TN2009000137A1/fr unknown
- 2009-04-21 IL IL198273A patent/IL198273A/en active IP Right Grant
- 2009-06-04 EC EC2009009387A patent/ECSP099387A/es unknown
- 2009-06-04 CO CO09057915A patent/CO6220908A2/es active IP Right Grant
- 2009-06-04 HN HN2009001131A patent/HN2009001131A/es unknown
- 2009-06-05 SV SV2009003288A patent/SV2009003288A/es unknown
- 2009-06-05 CR CR10838A patent/CR10838A/es unknown
- 2009-06-05 CU CU20090103A patent/CU23796B7/es active IP Right Grant
- 2009-06-05 DO DO2009000135A patent/DOP2009000135A/es unknown
- 2009-06-05 GT GT200900154A patent/GT200900154A/es unknown
- 2009-06-29 MA MA32057A patent/MA31283B1/fr unknown
- 2009-07-03 NO NO20092529A patent/NO342348B1/no unknown
- 2009-07-03 ZA ZA200904691A patent/ZA200904691B/xx unknown
2013
- 2013-06-03 US US13/908,566 patent/US20130261113A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1217953A1 (zh)	2017-01-27
CN105254634A (zh)	2016-01-20
ES2572189T3 (es)	2016-05-30
USRE46856E1 (en)	2018-05-22
AU2007328008B2 (en)	2014-03-13
BRPI0720178B8 (pt)	2021-05-25
WO2008070150A1 (fr)	2008-06-12
CA2671614C (fr)	2016-01-26
MY157944A (en)	2016-08-30
CN108774232B (zh)	2022-08-09
NO20092529L (no)	2009-08-27
BRPI0720178A2 (pt)	2013-12-24
NO342348B1 (no)	2018-05-07
EP2096919A4 (fr)	2010-11-17
EP2096919B1 (fr)	2016-03-02
SI2096919T1 (sl)	2016-06-30
TW200840582A (en)	2008-10-16
CU20090103A7 (es)	2011-12-28
PA8759601A1 (es)	2009-02-09
IL198273A0 (en)	2009-12-24
PL2096919T3 (pl)	2016-08-31
JP2010511718A (ja)	2010-04-15
KR20090096440A (ko)	2009-09-10
IL198273A (en)	2015-07-30
CN105254634B (zh)	2022-05-27
TWI406662B (zh)	2013-09-01
PE20081444A1 (es)	2008-11-29
HUE028773T2 (en)	2017-01-30
US8466283B2 (en)	2013-06-18
CO6220908A2 (es)	2010-11-19
CL2007003508A1 (es)	2008-07-04
UA96965C2 (ru)	2011-12-26
MX2009006001A (es)	2009-06-16
AR064106A1 (es)	2009-03-11
US20110083984A1 (en)	2011-04-14
BRPI0720178B1 (pt)	2019-04-09
CU23796B7 (es)	2012-03-15
CA2671614A1 (fr)	2008-06-12
CR10838A (es)	2009-11-05
UY30761A1 (es)	2008-07-03
US20130261113A1 (en)	2013-10-03
DK2096919T3 (en)	2016-05-17
JP5326092B2 (ja)	2013-10-30
RS56045B1 (sr)	2017-09-29
DOP2009000135A (es)	2009-06-30
EA018839B1 (ru)	2013-11-29
HN2009001131A (es)	2012-02-06
CN108774232A (zh)	2018-11-09
JO3147B1 (ar)	2017-09-20
MA31283B1 (fr)	2010-04-01
EA200900733A1 (ru)	2009-12-30
GT200900154A (es)	2012-01-17
EP2096919A1 (fr)	2009-09-09
SG177170A1 (en)	2012-01-30
CN101631464A (zh)	2010-01-20
ZA200904691B (en)	2010-09-29
ECSP099387A (es)	2009-11-30
SV2009003288A (es)	2009-10-02
AU2007328008A1 (en)	2008-06-12
CN101631464B (zh)	2022-12-06
NZ577342A (en)	2012-01-12
KR101501785B1 (ko)	2015-03-11
CN115724847A (zh)	2023-03-03

Publication	Publication Date	Title
UA96965C2 (ru)	2011-12-26	ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
PH12013500938A1 (en)	2013-07-08	Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009091550A8 (fr)	2010-08-26	Dérivés de 2,3-dihydroimidazo [1,2-c] quinazoline à substitution sulfone utilisés pour traiter des troubles hyperproliférants et des maladies associées à l'angiogénèse
WO2007064931A3 (fr)	2007-07-19	Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
MY143795A (en)	2011-07-15	Tetrahydropyridoindole derivatives
MY144992A (en)	2011-12-15	Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2005004818A3 (fr)	2005-05-06	Composes heterocycliques et leur utilisation comme agents anticancereux
MX2009012000A (es)	2009-11-19	Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
MY191349A (en)	2022-06-17	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX2009004745A (es)	2009-05-22	Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
DE602005021770D1 (de)	2010-07-22	Indol-1-yl-essigsäurederivate
TW200633978A (en)	2006-10-01	2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
TW200745136A (en)	2007-12-16	4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
TW200628468A (en)	2006-08-16	Bicyclononene derivatives
WO2007075650A3 (fr)	2007-11-15	Derives substitues de la pyrimidine utilisables dans le traitement du cancer et d'autres affections
MY148611A (en)	2013-05-15	Imino-imidazo-pyridine derivatives having antithrombotic activity
TN2013000204A1 (en)	2014-11-10	Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TH85706B (th)	2021-12-07	อนุพันธ์ 2,3-ไดไฮโดรอิมิดาโซ[1,2-c]ควินาโซลีนถูกแทนที่ (Substituted 2,3-dihydromidazo[1,2-c]quinazoline Derivatives) ซึ่งเป็นประโยชน์สำหรับการรักษาความผิดปกติด้านงอกขยายเกินปกติ และ โรคที่มีส่วนสัมพันธ์กับการก่อเกิดหลอดเลือดใหม่
TH149016A (th)	2016-04-26	อนุพันธ์ 2,3-ไดไฮโดรอิมิดาโซ[1,2-c]ควินาโซลีนถูกแทนที่ (Substituted 2,3-dihydromidazo[1,2-c]quinazoline Derivatives) ซึ่งเป็นประโยชน์สำหรับการรักษาความผิดปกติด้านงอกขยายเกินปกติ และ โรคที่มีส่วนสัมพันธ์กับการก่อเกิดหลอดเลือดใหม่
TW200603791A (en)	2006-02-01	Compounds and compositions as cathepsin S inhibitors
WO2006110447A3 (fr)	2007-01-18	Derives de pyrimidine
CY1117512T1 (el)	2017-04-26	Υποκατεστημενα παραγωγα 2,3-δiυδpoϊmiδazo[1,2-c] κιναζολινης χρησιμα στη θεραπευτικη αντιμετωπιση υπερ-πολλαπλασιαστικων διαταραχων και παθησεων που σχετιζονται με την αγγειογενεση
UA86813C2 (ru)	2009-05-25	Ингибиторы бета-гидроксистероидной дегидрогеназы типа 1